Preferred Label : Anti-CD11b Monoclonal Antibody ASD141;
NCIt definition : A monoclonal antibody directed against the CD11b (integrin alpha-M; ITGAM; integrin
alpha M chain) subunit of MAC-1 (integrin alphaM/beta2; CD11b/CD18; CR3), with potential
innate immune checkpoint inhibitory, immunomodulating and antineoplastic activities.
Upon administration, anti-CD11b monoclonal antibody ASD141 targets, binds to and blocks
the CD11b subunit of the Mac-1 receptor, thereby preventing TLT-1 (pro-T) binding
to CD11b receptors on immature, innate myeloid cells in the tumor microenvironment
(TME). This prevents CD11b-mediated signaling, abrogates the TLT-1-driven immunosuppressive
nature of the TME and modulates the TME. This reduces infiltration of immunosuppressive
tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs),
activates the innate immune system, and promotes infiltration of antigen-presenting
cells (APCs). Specifically, the infiltration of mature interleukin-12 (IL-12)-producing
dendritic cells (DCs) increases, and pro-inflammatory macrophage polarization is induced
while immunosuppressive macrophage polarization is suppressed. The DC- and macrophage-driven
anti-tumor immune responses along with the increase in cytotoxic T-lymphocytes (CTLs)
and production of interferon-gamma (IFN-g) kill tumor cells and suppress tumor growth.
CD11b, a member of the integrin family of cell adhesion receptors and alpha-chain
of the integrin receptor alphaMbeta2, is highly expressed on immune cells and is a
negative regulator of immune suppression. TLT-1, a key regulatory protein released
from platelets, plays a key role in the induction of the immune suppressive environment
in the tumor and immune checkpoint blockade. Its expression in the TME is correlated
with poor prognosis.;
Molecule name : ASD-141; ASD 141;
Origin ID : C207272;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
